Abstract: Drug nanocrystals are a versatile option for drug delivery purposes, and while the
number of poorly soluble drug materials is all the time increasing, more research in this area is
performed. Drug nanocrystals have a simple structure—a solid drug core is surrounded by a layer of stabilizing agent. However, despite the considerably simple structure, the selection of an appropriate stabilizer for a certain drug can be challenging. Mostly, the stabilizer selection is based purely on the requirement of physical stability, e.g., maintaining the nanosized particle size as long as possible after the formation of drug nanocrystals. However, it is also worth taking into account that stabilizer can affect the bioavailability in the final formulation via interactions with cells and cell layers. In addition, formation of nanocrystals is only one process step, and for the final formulation, more excipients are often added to the composition. The role of the stabilizers in the final formulation can be more than only stabilizing the nanocrystal particle size. A good example is the stabilizer’s role as cryoprotectant during freeze drying. In this review, the stabilizing effect, role of stabilizers in final nano crystalline formulations, challenges in reaching in vitro–in vivo correlation with nanocrystalline products, and stabilizers’ effect on higher bioavailability are discussed.
Division of Pharmaceutical Chemistry and Technology, P.O. Box 56 (Viikinkaari 5 E), University of Helsinki,
00014 Helsinki, Finland; annika.tuomela@gmail.com (A.T.); jouni.hirvonen@helsinki.fi (J.H.)
* Correspondence: leena.peltonen@helsinki.fi; Tel.: +358-50-448-0726